TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02496975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
Study: NCT04496830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMAscan
Description: Analysis of previously donated cerebrospinal fluid using a SOMAscan assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMAscan
Description: Analysis of previously donated cerebrospinal fluid using a SOMAscan assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMAscan
Description: Analysis of previously donated cerebrospinal fluid using a SOMAscan assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMAscan
Description: Analysis of previously donated cerebrospinal fluid using a SOMAscan assay
Study: NCT03923946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion focused therapy
Description: Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
Study: NCT02675088

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high-dose TRT
Description: every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose TRT
Description: every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
Study: NCT01824030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guided PCI
Description: FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided PCI
Description: OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
Study: NCT03196167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
Study: NCT03837028

Intervention type: OTHER
Intervention: FSFI
Description: Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.

Intervention type: OTHER
Intervention: FSFI
Description: Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
Study: NCT01203007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailored diet
Description: Tailored diet according to demonstrated food sensitivity, 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low antigen content diet
Description: Low-antigen content diet for one month
Study: NCT03302767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological and Social Consultation
Description: Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
Study: NCT04778124

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)
Description: All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excision of thrombosed hemorrhoid / Hemorrhoidectomy /
Description: One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
Study: NCT03881488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-471
Description: IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-471
Description: IV infusion every 2 weeks
Study: NCT03044236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
Study: NCT03881488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-471
Description: IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-471
Description: IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: IV infusion every 6 weeks
Study: NCT03044236

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
Study: NCT00750022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized IC treatment
Description: Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
Study: NCT03766984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 25 mg
Description: Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg
Description: Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg
Description: Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
Study: NCT01342094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-111 ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol ophthalmic solution 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ophthalmic solution
Study: NCT02004626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase
Description: Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kollagenase
Description: Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records.
Study: NCT01061528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine
Description: Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine
Description: Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
Study: NCT01006161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: High dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SCH 527123
Description: Placebo to match SCH 527123
Study: NCT04627129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 and Itraconazole
Description: Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
Study: NCT03881488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: IV infusion every 6 weeks
Study: NCT00661778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in glass vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study: NCT01425814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977
Description: Dry powder inhalation,Once daily, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977
Description: Dry powder inhalation,Once daily, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977
Description: Dry powder inhalation,Once daily, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977
Description: Dry powder inhalation,Once daily, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Dry powder inhalation (capsule),single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
Study: NCT00002529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
Study: NCT00661778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study: NCT03174054

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
Study: NCT01306864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray Kit
Description: Hemostasis of Arterial GI Bleeding
Study: NCT03823534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: An IV normal saline placebo prepared by the hospital pharmacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 500 mg PO Q4 hours PRN for mild pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 500 mg PO Q4 hours PRN for mild pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone Acetaminophen
Description: oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Acetaminophen
Description: oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: morphine IV PRN (or other opioid) for severe breakthrough pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine IV PRN (or other opioid) for severe breakthrough pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen
Description: At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
Study: NCT02421081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vessel microsurgery
Description: That is a surgery ro repair artery laceration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tendon repair
Description: That is a surgery ro repair tendon cut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tendon repair
Description: That is a surgery ro repair tendon cut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve microsurgery
Description: That is a surgery ro repair median/ ulnar/ radial nerve cut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve microsurgery
Description: That is a surgery ro repair median/ ulnar/ radial nerve cut.
Study: NCT04456543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure monitoring
Description: garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pressure monitoring
Description: garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
Study: NCT03702530

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2x 50 L3 larvae infection
Description: After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
Study: NCT01604057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-034 Low Dose Nasal Spray
Description: Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-034 Mid Dose Nasal Spray
Description: Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-034 High Dose Nasal Spray
Description: Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20 mcg subcutaneous daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray
Study: NCT00555048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study: NCT05112146

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein microgel
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein microgel
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Oral administration
Study: NCT04438668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centaflow and Standard Care
Description: The intervention is screening methods

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The intervention is screening methods
Study: NCT03061552

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sonographic measurement of inferior vena cava diameter
Description: pre-dialysis measurement of inferior vena cava diameter using echocardiography
Study: NCT02590042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSC-SVF-002
Description: ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)
Study: NCT00750022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
Study: NCT00335335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodixanol
Study: NCT00604201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
Study: NCT00164749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and ginkgo extract
Description: Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin and ginkgo extract
Description: 1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
Study: NCT00002529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
Study: NCT00164749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin and ginkgo extract
Description: 4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
Study: NCT00720226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 100 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill daily
Study: NCT00671073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oglemilast
Description: Oglemilast low dose, oral administration, once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral administration, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oglemilast
Description: Oglemilast middle dose, oral administration, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oglemilast
Description: Oglemilast high dose, oral administration, once daily for 12 weeks
Study: NCT03504761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore Optical Biopsy System
Description: Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
Study: NCT04658316

Intervention type: BEHAVIORAL
Intervention: Iowa Oral Performance Instrument
Description: Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure

Intervention type: BEHAVIORAL
Intervention: Iowa Oral Performance Instrument
Description: Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure

Intervention type: BEHAVIORAL
Intervention: Iowa Oral Performance Instrument
Description: Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure

Intervention type: BEHAVIORAL
Intervention: Iowa Oral Performance Instrument
Description: Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure

Intervention type: BEHAVIORAL
Intervention: Iowa Oral Performance Instrument
Description: Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure

Intervention type: BEHAVIORAL
Intervention: Iowa Oral Performance Instrument
Description: Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure